Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016)

References

• Jacobs E, Hoyer A, Brinks R, et al. Healthcare costs of type 2 diabetes in Germany. Diabet Med. 2017;34:855–861.
   PubMed Web of Science ®Google Scholar
• Rothenbacher D, Rüter G, Saam S, et al. [Management of patients with type 2 diabetes. Results in 12 practices of general practitioners]. Dtsch Med Wochenschr. 2002;127:1183–1187. German.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Henschke C, Blümel M, et al. Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. Dtsch Arztebl Int. 2014;111:453–463.
   PubMed Web of Science ®Google Scholar
• Laxy M, Knoll G, Schunk M, et al. Quality of diabetes care in Germany improved from 2000 to 2007 to 2014, but improvements diminished since 2007. Evidence from the population-based KORA studies. PLoS One. 2016;11:e0164704.
   PubMed Web of Science ®Google Scholar
• Müller N, Heller T, Freitag MH, et al. Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data. Diabet Med. 2015;32:951–957.
   PubMed Web of Science ®Google Scholar
• Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47:617–626.
   PubMed Web of Science ®Google Scholar
• Kowall B, Rathmann W, Kostev K. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis. Diabetes Care. 2015;38:59–65.
   PubMed Web of Science ®Google Scholar
• Swart E, Gothe H, Geyer S, et al. [Good practice of secondary data analysis (GPS): guidelines and recommendations]. Gesundheitswesen. 2015;77:120–126.
   PubMed Web of Science ®Google Scholar
• Heidemann C, Du Y, Paprott R, et al. Temporal changes in the prevalence of diagnosed diabetes, undiagnosed diabetes and prediabetes: findings from the German Health Interview and Examination Surveys in 1997–1999 and 2008–2011. Diabet Med. 2016;33:1406–1414.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537–547.
   PubMed Web of Science ®Google Scholar
• Du Y, Heidemann C, Schaffrath Rosario A, et al. Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997–1999 and 2008–2011. BMJ Open Diabetes Res Care. 2015;3:e000135.
   PubMed Web of Science ®Google Scholar
• Bramlage P, Lanzinger S, Rathmann W, et al. Dyslipidaemia and its treatment in patients with type 2 diabetes: a joint analysis of the German DIVE and DPV registries. Diabetes Obes Metab. 2016 Sep 4. [Epub ahead of print].
   PubMedGoogle Scholar
• Mata-Cases M, Franch-Nadal J, Real J, et al. Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study. BMJ Open. 2016;6:e012463.
   PubMed Web of Science ®Google Scholar
• Baviera M, Monesi L, Marzona I, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy’s Lombardy Region: a large population-based study. Diabetes Res Clin Pract. 2011;93:123–130.
   PubMed Web of Science ®Google Scholar
• Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6:e010210.
   PubMed Web of Science ®Google Scholar
• Geier AS, Wellmann I, Wellmann J, et al. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;106:73–80.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care. 2016;39(Suppl 2):S154–64.
   PubMed Web of Science ®Google Scholar
• Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab. 2013;15:55–61.
   PubMed Web of Science ®Google Scholar
• Kostev K, Rex J, Rockel T, et al. Effects of selected antidiabetics on weight loss – a retrospective database analysis. Prim Care Diabetes. 2015;9:74–77.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–259.
   PubMed Web of Science ®Google Scholar
• Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2017 Aug 3. [Epub ahead of print]. DOI:10.1111/dom.13077
   Web of Science ®Google Scholar
• Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5:709–717.
   PubMed Web of Science ®Google Scholar
• Udell JA, Yuan Z, Rush T, et al. Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study. Circulation. 2017 Nov 13. pii:CIRCULATIONAHA.117.031227. [Epub ahead of print].
   Google Scholar
• Danne T, Bluhmki T, Seufert J, et al.; DIVE study group. Treatment intensification using long-acting insulin-predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord. 2015;15:54.
   PubMed Web of Science ®Google Scholar
• Bongaerts BW, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36:1141–1146.
   PubMed Web of Science ®Google Scholar
• Mehra M, Merchant S, Gupta S, et al. Diabetic peripheral neuropathy: resource utilization and burden of illness. J Med Econ. 2014;17:637–645.
   PubMedGoogle Scholar
• Hermanns N, Caputo S, Dzida G, et al. Screening, evaluation and management of depression in people with diabetes in primary care. Prim Care Diabetes. 2013;7:1–10.
   PubMed Web of Science ®Google Scholar
• Finger JD, Busch MA, Du Y, et al. Time trends in cardiometabolic risk factors in adults. Dtsch Arztebl Int. 2016;113:712–719.
   PubMed Web of Science ®Google Scholar
• Bramesfeld A, Grobe T, Schwartz FW. Prevalence of depression diagnosis and prescription of antidepressants in East and West Germany: an analysis of health insurance data. Soc Psychiatry Psychiatr Epidemiol. 2010;45:329–335.
   PubMed Web of Science ®Google Scholar